Nyxoah (NASDAQ:NYXH) versus Zimmer Biomet (NYSE:ZBH) Head to Head Survey

Zimmer Biomet (NYSE:ZBH) and Nyxoah (NASDAQ:NYXH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Zimmer Biomet and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2	14	6	0	2.18
Nyxoah	1	1	2	0	2.25

Zimmer Biomet currently has a consensus price target of $103.00, suggesting a potential upside of 16.58%. Nyxoah has a consensus price target of $4.26, suggesting a potential upside of 213.38%. Given Nyxoah’s stronger consensus rating and higher probable upside, analysts clearly believe Nyxoah is more favorable than Zimmer Biomet.

Profitability

This table compares Zimmer Biomet and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.48%	13.12%	7.23%
Nyxoah	-443.16%	-178.90%	-81.83%

Valuation and Earnings

This table compares Zimmer Biomet and Nyxoah”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23 billion	2.05	$705.20 million	$4.11	21.50
Nyxoah	$21.66 million	2.43	-$101.92 million	($2.52)	-0.54

Zimmer Biomet has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Zimmer Biomet has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Summary

Zimmer Biomet beats Nyxoah on 9 of the 14 factors compared between the two stocks.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.